Proteomics International Reports FY2026 Revenue Up 3 Percent, Losses Widen

Revenue Growth Overshadowed by Rising Losses

Proteomics International Laboratories Ltd (ASX:PIQ) posted a modest 3% increase in total revenue and other income to AUD 3.61 million for the year ended 30 June 2026. However, this was accompanied by a 5.5% rise in net loss after tax attributable to shareholders, which widened to AUD 8.56 million. The company’s ongoing investment in commercialisation, clinical validation, and laboratory expansion continues to weigh on the bottom line.

Strategic Reset and Operational Restructuring

FY2026 marked a turning point for Proteomics International as it moved away from its direct-to-consumer (DTC) model in Australia and the United States, following a strategic and operational review. The company suspended the DTC approach to focus on targeted clinical adoption, controlled market introductions, and distribution partnerships. An organisational restructure eliminated approximately 25% of positions, delivering annualised cost savings exceeding AUD 1 million.

The leadership transition was a notable feature of the year, with David Morris appointed CEO and Managing Director in January 2026, bringing extensive global healthcare and medical technology experience. Founder Dr Richard Lipscombe retired after 25 years, leaving a scientific foundation that the new management aims to convert into sustainable commercial success.

Promarker® Portfolio Advances with Clinical and Commercial Milestones

The company advanced its proprietary Promarker® portfolio, including Promarker®D, Promarker®Eso, and Promarker®Endo, each targeting significant clinical needs such as diabetic kidney disease, oesophageal cancer risk, and endometriosis diagnosis. Promarker®D received a dedicated CPT PLA billing code from the American Medical Association, facilitating billing and payer engagement in the US, though Medicare reimbursement remains pending comprehensive technical assessments.

Clinical validation results for Promarker®D and Promarker®Eso were published in respected journals and presented at key conferences, reinforcing clinical credibility. Promarker®Endo secured a AUD 500,000 Western Australian Government commercialisation grant and achieved patent protection in both the US and Australia, bolstering its intellectual property portfolio.

Laboratory Accreditation and Capacity Expansion

Proteomics International strengthened its laboratory infrastructure, achieving National Association of Testing Authorities (NATA) ISO 15189 accreditation for its Australian operations and College of American Pathologists (CAP) accreditation for its US laboratory in Irvine, California. The Australian Precision Diagnostics Facility opened in November 2025, equipped with high-throughput mass spectrometry and automated immunoassay platforms designed to support scalable clinical testing.

Exclusive Distribution Deal with Healius

Post period, Proteomics International executed a three-year exclusive national distribution agreement with Healius Limited (ASX:HLS) for the Promarker® portfolio in Australia. This partnership grants access to Healius’ extensive pathology network of over 2,000 patient collection centres and established referrer relationships, while Proteomics International retains responsibility for testing, clinical reporting, and regulatory compliance. The phased commercial rollout is planned for FY2027, although commercial outcomes remain subject to clinician adoption, reimbursement progress, and market conditions.

Financial Position and Going Concern Considerations

Cash and cash equivalents stood at AUD 3.5 million at year-end, down from AUD 11 million the previous year, with net assets declining to AUD 5.55 million. Operating cash outflows amounted to AUD 5.87 million, reflecting ongoing investment in growth initiatives. The company anticipates receiving approximately AUD 2 million from the Research and Development Tax Incentive in the first half of FY2027.

Notably, the auditors highlighted a material uncertainty regarding the company’s ability to continue as a going concern, citing ongoing losses and cash burn. However, Proteomics International has a track record of successful capital raises and R&D tax incentive claims, which management expects to continue leveraging.

What Lies Ahead for Proteomics International

Looking forward, Proteomics International aims to translate its proteomics platform into clinically adopted diagnostics with sustainable commercial pathways. Key priorities include implementing the Healius distribution agreement, advancing reimbursement strategies in Australia and the US, and preparing Promarker®Endo for controlled market introduction. The company’s commercial success will hinge on clinician acceptance, workflow integration, reimbursement outcomes, and partner execution amid ongoing market uncertainties.

Investors might watch closely how effectively the company navigates these complex commercialization challenges, especially given the material uncertainty around its financial sustainability. The upcoming shareholder meeting will also be pivotal, with a revised executive incentive package under consideration following recent share price volatility.